tiprankstipranks
SomnoMed Limited Sees Growth and Innovation in 2024
Company Announcements

SomnoMed Limited Sees Growth and Innovation in 2024

Somnomed Limited (AU:SOM) has released an update.

Stay Ahead of the Market:

SomnoMed Limited has undergone significant changes with the appointment of co-CEOs Karen Borg and Amrita Blickstead, who have driven growth and operational improvements. The company reported FY24 revenue of $91.7 million and has focused on strengthening its manufacturing capabilities to meet rising product demand. With recent FDA clearance of its innovative Rest Assure® device, SomnoMed aims for continued growth and improved financial stability.

For further insights into AU:SOM stock, check out TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles